Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: A double-blind placebo-controlled trial followed by an open-label extension

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Vakhapova, Veronika ^a   Richter, Yael ^b   Cohen, Tzafra ^b   Herzog, Yael ^b   Korczyn, Amos D ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b Enzymotec Ltd   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID; PHOSPHATIDYLSERINE; PLACEBO; UNCLASSIFIED DRUG; VAYACOG;

AGED; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EYE INFLAMMATION; FALLING; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HAND FRACTURE; HEADACHE; HEART RATE; HEMORRHOID HEMORRHAGE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; INCREASED APPETITE; LIMB INJURY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MOOD DISORDER; PNEUMONIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TENESMUS; TRANSITIONAL BLINDNESS; URINARY TRACT INFECTION; WEIGHT; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT;

BLOOD; BLOOD PRESSURE; BODY WEIGHT; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; HEART RATE; HUMANS; MALE; PHOSPHATIDYLSERINES;

EID: 79959582435     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-79     Document Type: Article

References (29)

1. Vance JE, Steenbergen R. Metabolism and functions of phosphatidylserine. Prog Lipid Res 2005, 44(4):207-234. 10.1016/j.plipres.2005.05.001, 15979148.
2. Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC. Effects of phosphatidylserine in age-associated memory impairment. Neurology 1991, 41(5):644-649.
3. Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano) 1993, 5(2):123-133.
4. Amaducci L. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull 1988, 24(1):130-134.
5. Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull 1992, 28(1):61-66.
6. Palmieri G, Palmieri R, Inzoli MR, Lombardi G, Sottini C, Tavolato B, Giometto B. Double blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clinical Trials Journal 1987, 24(1):73-83.
7. Puca FM, Bavarese MA, Minervini MG. Exploratory trial of PS efficacy in mildly demented patients. Cinical Trials Journal 1987, 24:94-98.
8. Rabboni M, Maggioni FS, Giannelli A, Beinat L. Neuroendocrine and behavioral effects of PS in elderly patients with abiotrophic or vascular dementia or mild depression. Clinical Trials Journal 1990, 27:230-240.
9. Jager R, Purpura M, Kingsley M. Phospholipids and sports performance. J Int Soc Sports Nutr 2007, 4:5. 10.1186/1550-2783-4-5, 1997116, 17908342.
10. Benton D, Donohoe RT, Sillance B, Nabb S. The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. Nutr Neurosci 2001, 4(3):169-178.
11. Hellhammer J, Fries E, Buss C, Engert V, Tuch A, Rutenberg D, Hellhammer D. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. Stress 2004, 7(2):119-126. 10.1080/10253890410001728379, 15512856.
12. Jorissen BL, Brouns F, Van Boxtel MP, Ponds RW, Verhey FR, Jolles J, Riedel WJ. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. Nutr Neurosci 2001, 4(2):121-134.
13. Schreiber S, Kampf-Sherf O, Gorfine M, Kelly D, Oppenheim Y, Lerer B. An open trial of plant-source derived phosphatydilserine for treatment of age-related cognitive decline. Isr J Psychiatry Relat Sci 2000, 37(4):302-307.
14. Jorissen BL, Brouns F, Van Boxtel MP, Riedel WJ. Safety of soy-derived phosphatidylserine in elderly people. Nutr Neurosci 2002, 5(5):337-343. 10.1080/1028415021000033802, 12385596.
15. Vaisman N, Kaysar N, Zaruk-Adasha Y, Pelled D, Brichon G, Zwingelstein G, Bodennec J. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr 2008, 87(5):1170-1180.
16. Vaisman N, Pelled D. n-3 phosphatidylserine attenuated scopolamine-induced amnesia in middle-aged rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(6):952-959. 10.1016/j.pnpbp.2009.04.021, 19414058.
17. Vakhapova V, Cohen T, Richter Y, Herzog Y, Korczyn AD. Phosphatidylserine Containing omega-3 Fatty Acids May Improve Memory Abilities in Non-Demented Elderly with Memory Complaints: A Double-Blind Placebo-Controlled Trial. Dement Geriatr Cogn Disord 29(5):467-474.
18. Crook TH, Feher EP, Larrabee GJ. Assessment of memory complaint in age-associated memory impairment: the MAC-Q. Int Psychogeriatr 1992, 4(2):165-176. 10.1017/S1041610292000991, 1477304.
19. Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 2004, 62(2):275-280.
20. Albanese E, Dangour AD, Uauy R, Acosta D, Guerra M, Guerra SSG, Huang Y, Jacob KS, Llibre de Rodriguez J, Noriega LH, et al. Dietary fish and meat intake and dementia in Latin America, China, and India: a 10/66 Dementia Research Group population-based study. Am J Clin Nutr 2009, 90(2):392-400. 10.3945/ajcn.2009.27580, 3008672, 19553298.
21. Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, Burke GL, Carlson MC. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005, 65(9):1409-1414. 10.1212/01.wnl.0000183148.34197.2e, 16275829.
22. Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S, Lodi L. Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur J Clin Investigation 2005, 35:691-699.
23. Terano T, Fujishiro S, Ban T, Yamamoto K, Tanaka T, Noguchi Y, Tamura Y, Yazawa K, Hirayama T. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids 1999, 34(Suppl):S345-346.
24. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N, Stedman M. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010, 6(6):456-464. 10.1016/j.jalz.2010.01.013, 20434961.
25. Wheeler KP, Whittam R. ATPase activity of the sodium pump needs phosphatidylserine. Nature 1970, 225(5231):449-450. 10.1038/225449a0, 4243739.
26. Bittova L, Stahelin RV, Cho W. Roles of ionic residues of the C1 domain in protein kinase C-alpha activation and the origin of phosphatidylserine specificity. J Biol Chem 2001, 276(6):4218-4226. 10.1074/jbc.M008491200, 11029472.
27. Vance JE. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res 2008, 49(7):1377-1387. 10.1194/jlr.R700020-JLR200, 18204094.
28. Pepeu G, Pepeu IM, Amaducci L. A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain?. Pharmacol Res 1996, 33(2):73-80. 10.1006/phrs.1996.0013, 8870022.
29. Pepping J. Phosphatidylserine. American Journal of Health-System Pharmacy 1999, 56:2043-2044.